AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06703970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid Injection
Description: 5 milliliters (mL) injection of corticosteroid (1cc Kenalog, 4cc Xylocaine) Kenalog - 40 (triamcinolone acetonide injectable suspension, USP) Xylocaine - MPF (lidocaine HCl Injection, USP)
Study NCT06703970 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma Joint Injection
Description: \~3 milliliters (mL) injection of autologous PRP Magellan Autologous Concentration System, ISTO Biologics
Study NCT06703749 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment with BTL-899M
Description: The treatment administration phase will consist of four (4) treatments, delivered 5-10 days apart. The applicators of BTL-899M will be applied over the designated area. Each therapy session will last 30 minutes. The starting intensity of the radiofrequency energy will be set to 100%. The intensities of both energies will be adjusted according to the patient's feedback.
Study NCT06703749 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Treatment with BTL-899M with intensities below therapeutic threshold
Description: The treatment administration phase will consist of four (4) treatments, delivered 5-10 days apart. The applicators of BTL-899M will be applied over the designated area. Each therapy session will last 30 minutes. The intensities of both energies will be set below the therapeutic threshold.
Study NCT06702813 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-Frequency Oscillatory Ventilation
Description: Administer 10 minutes of high-frequency oscillatory ventilation in awake ICU patients.
Study NCT06453720 — intervention group
Intervention type: PROCEDURE
Intervention: Colonoscopy
Description: A colonoscopy will be performed as part of routine clinical care for all participants, with the study not requiring any additional scheduling commitments outside of routine care.
Study NCT06463756 — intervention group
Intervention type: OTHER
Intervention: AI
Description: Radiomics extracts quantitative information from medical images to generate high-dimensional feature vectors for analysis. It aims to provide insights into disease processes and improve diagnosis.~Deep learning utilizes neural networks with multiple layers to learn complex patterns from data. In medical imaging, it enables accurate and efficient analysis for disease detection and diagnosis.
Study NCT06316960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avapritinib
Description: 50mg/m2/day for weighing bodyweight >10kg, 1.65mg/kg/day for weighing ≤ 10kg, po, qd, d1-28.
Study NCT06316960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine Injection
Description: 75mg/m2/d for weighing >10kg, 2.5mg/kg/d for weighing ≤ 10kg, d1-7, ivgtt, qd, more than 3 hours. Azacitidine and decitabine cannot be used simultaneously.
Study NCT06316960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine Injection
Description: 20mg/m2/d for weighing >10kg, 0.67mg/kg/d for weighing ≤ 10kg, d1-5, ivgtt, qd, more than 3 hours. Azacitidine and decitabine cannot be used simultaneously.
Study NCT06316960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin Hydrochloride
Description: 5mg/m2/day for weighing >10kg, 0.17mg/kg/day for weighing ≤ 10kg, d 6, 8, 10 (d 8, 10, 12 for azacitidine) ivgtt, qod, more than 1 hour at 10 am.
Study NCT06316960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 10mg/m2/day for weighing >10kg, 0.33mg/kg/day for weighing ≤ 10kg, d6-15 （d8-17 for azacitidine ）, s.c., q12h.
Study NCT06316960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor
Description: 300ug/day for weighing >10kg, 10ug/kg/day for weighing ≤10kg, d0-5, s.c., qd.
Study NCT06204536 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tech-enabled ABA treatment planning
Description: The tech-enabled ABA treatment planning will involve the use of a proprietary MLA integrated within a proprietary software application for use on a tablet, phone, or other smart device by BCBAs (one proprietary software application, one non-proprietary software application). The proprietary application provides functionality for treatment plan development, including templates and centralized resource availability. This tech will be used as adjunct or auxiliary tools to develop and manage ABA treatment plans. The proposed period of time for this intervention (the latter portion of the study subsequent to the non-interventional phases) will be 24 months.
Study NCT06297941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REM-422
Description: REM-422 is a first in class, small molecule mRNA inhibitor that reduces expression of the MYB transcription factor~REM-422 will be administered orally once daily
Study NCT05358392 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: emotional freedom technique (EFT)
Description: EFT is an energy psychotherapy derivative application, consisting of cognitive and somatic components, used to heal personal negative emotions and related emotional and physical disorders. Stress hormones are secreted in response to the stress response in the person, and then the amygdala and other cerebral parts that respond to stress are activated. There are basic steps to be followed in EFT application; By giving a message to the emotional body (subconscious) with suggestion sentences, clicks are made on the twelve energy meridian endpoints (acupressure points).
Study NCT05957913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada (tenofovir/emtricitabine)
Description: Doses and route of administration of the study drug will be kept the same as for the FDA-approved indication of HIV-1 prevention in healthy individuals. The study drug is not FDA-approved for the treatment of multiple sclerosis.
Study NCT05623449 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical examination
Description: Current medications (only those prescribed to treat pain, anxiety and depression), non-drug treatment(s) prior to treatment in hypnosis as well as any ongoing treatment(s).
Study NCT05623449 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical examination
Description: Current medications (only those prescribed to treat pain, anxiety and depression), non-drug treatment(s) prior to treatment in hypnosis as well as any ongoing treatment(s).
Study NCT05623449 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anxiety and Depression Scale (HAD)
Description: To screen for anxious and depressive symptoms
Study NCT05623449 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Anxiety and Depression Scale (HAD)
Description: To screen for anxious and depressive symptoms
Study NCT05623449 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pain scale
Description: Measurement of pain intensity
Study NCT05623449 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pain scale
Description: Measurement of pain intensity
Study NCT05623449 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hypnosis consultation
Description: 5 hypnosis consultation
Study NCT05623449 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hypnosis consultation
Description: 5 hypnosis consultation
Study NCT05623449 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maintenance
Description: Qualitative assessment
Study NCT05623449 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maintenance
Description: Qualitative assessment
Study NCT05623449 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Data collection
Description: Age, sex, socio-professional category, level of education, comorbidities, date of diagnosis of chronic peripheral neuropathic pain, distance between home and hospital.
Study NCT05623449 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Data collection
Description: Age, sex, socio-professional category, level of education, comorbidities, date of diagnosis of chronic peripheral neuropathic pain, distance between home and hospital.
Study NCT06180577 — intervention group
Intervention type: DEVICE
Intervention: Nerivio
Description: Nerivio is a prescribed Remote Electrical Neuromodulation (REN) device for treatment of migraine
Study NCT06025500 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 31P-Magnetic Resonance Spectroscopy (31P-MRS)
Description: 31P-Magnetic Resonance Spectroscopy will be performed during exercise testing.
Study NCT06224192 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Rocatinlimab Prefilled Syringe
Description: Prefilled Syringe (PFS) for subcutaneous (SC) injection self-administration of rocatinlimab.
Study NCT06224192 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Rocatinlimab AI
Description: AI for SC injection self-administration of rocatinlimab.
Study NCT06334354 — intervention group
Intervention type: OTHER
Intervention: Assessments
Description: Sociodemographics, Deficit Accumulation Questionnaires, Remote Cognitive Assessment, Deficit Accumulation Questionnaires,Remote Cognitive Assessment
Study NCT06334354 — intervention group
Intervention type: OTHER
Intervention: Assessment (Survivors Only)
Description: \*Tumor/Treatment Variables (Survivors Only)
Study NCT06334354 — intervention group
Intervention type: OTHER
Intervention: APOE and DNA Isolation
Description: Biospecimens procurement and processing
Study NCT06573697 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low-frequency continuous wave EA
Description: In each treatment session, the subjects will receive EA treatment. The selected acupoints for needling will be BL2, GB1, GB14, ST2, SI18, ST6, ST4, ST7, SJ17, EX-HN16, EX-HN5, on affected side, and LI4, bilaterally. After the de-qi sensation is achieved, electrical stimulator will be connected to BL2-GB1, and ST4-ST6, and 2Hz continuous wave will be used for 20 min.
Study NCT06573697 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: discontinuous wave EA
Description: In each treatment session, the subjects will receive EA treatment. The selected acupoints for needling will be BL2, GB1, GB14, ST2, SI18, ST6, ST4, ST7, SJ17, EX-HN16, EX-HN5, on affected side, and LI4, bilaterally. After the de-qi sensation is achieved, electrical stimulator will be connected to BL2-GB1, and ST4-ST6, and 40Hz discontinuous wave will be used for 20 min.
Study NCT06573697 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dilatational wave EA
Description: In each treatment session, the subjects will receive EA treatment. The selected acupoints for needling will be BL2, GB1, GB14, ST2, SI18, ST6, ST4, ST7, SJ17, EX-HN16, EX-HN5, on affected side, and LI4, bilaterally. After the de-qi sensation is achieved, electrical stimulator will be connected to BL2-GB1, and ST4-ST6, and 2/100Hz dilatational wave will be used for 20 min.
Study NCT04872686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.6% PVP-I Oral and nasal spray to asymptomatic to mild COVID-19 patient having multiple comorbidity
Description: Number of participants 20 asymptomatic to mild COVID -19 patients having multiple comorbidity who will receive intervention~Step 1: Selection of 20 patients randomly with no or mild symptoms and obtain their consent for the further tests.~Step 2: Collection of 2nd, 3rd and 4th sample from nasopharynx and oropharynx hourly Step 3: Data collection, data processing and analysis by using SPSS software
Study NCT04872686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.6% PVP-I Oral and nasal spray to healthy volunteer
Description: Number of participants 10 healthy individual who accept intervention 0.6% PVP-I oronasal spray~Step 1: Selection of 10 healthy volunteers randomly who will be selected for using 0.6% PVP-I Oro-Nasal spray 2 puff inside both nostrils and mouth 3 to 4 times a day for one month.~Step 2: Collection of blood \& urine of participants on day 0, 10, 20, 30 for determination of any change in biochemical marker (thyroid, kidney and liver functions will be done) Step 3: Data collection, data processing and analysis by using SPSS software
Study NCT05711745 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Calf myofascial technique
Description: A 3-pass superficial leg glide technique was applied first and then 5 minutes of the deep calf myofascial induction technique as described by Pilat.
Study NCT04756219 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contact Video
Description: No additional information necessary.
Study NCT04756219 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Contact Video
Description: No additional information necessary.
Study NCT04756219 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contact Text
Description: No additional information necessary.
Study NCT04756219 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Contact Text
Description: No additional information necessary.
Study NCT04756219 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Education Video
Description: No additional information necessary.
Study NCT04756219 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education Video
Description: No additional information necessary.
Study NCT04756219 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Education Text
Description: No additional information necessary.
Study NCT04756219 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education Text
Description: No additional information necessary.
Study NCT05363345 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bile duct stone removal
Description: Common bile duct stones (≧ 10 mm) are removed by using Vortic Catch V basket catheter or ordinary basket catheter following endoscopic papillary large balloon dilation.
Study NCT05363345 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: bile duct stone removal
Description: Common bile duct stones (≧ 10 mm) are removed by using Vortic Catch V basket catheter or ordinary basket catheter following endoscopic papillary large balloon dilation.
Study NCT06531733 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sleep Promoting (pink noise)
Description: Participants will be provided with comfortable headphones to wear throughout their daytime sleep opportunity. The headphones will deliver a continuous pink noise sound no greater than 50 decibels. Participants will be allowed to turn down the sound of the pink noise if they find it too loud. Participants will wear the headphones with no noise during the placebo condition.
Study NCT05960708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH35324
Description: Subcutaneous injection of YH35324
Study NCT05960708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab
Description: Subcutaneous injection of Omalizumab
Study NCT06531733 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wake Promoting (blue enriched light plus a nap)
Description: Participants randomized to the blue-enriched light and nap condition will have the blue-enriched light turned on during their nighttime stay in the lab. The light will be turned off for up to one hour during the nap. During the placebo condition, participants will have an overhead room light of \~150 lux illuminated throughout their nighttime stay in the lab. This light level reflects an older NASA standard which was used in the design of some Artemis vehicles. During the placebo condition, participants will be asked to engage in quiet activities such as reading for one hour.
Study NCT05960708 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection of None of active ingredient
Study NCT06343142 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nuts
Description: Isocaloric meal with nuts
Study NCT06343142 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nut-free meal
Description: Isocaloric meal without nuts
Study NCT05073536 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mini-sized MCE
Description: Enrolled participants were randomly allocated into the normal-sized MCE group or mini-sized MCE group in a 1:1 ratio.
Study NCT05073536 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: normal-sized MCE
Description: Enrolled participants were randomly allocated into the normal-sized MCE group or mini-sized MCE group in a 1:1 ratio.
Study NCT05398042 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone ester
Description: A daily dose of 3x20g of ketone ester supplementation during a six week intervention period
Study NCT05398042 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Medium Chain Triglyceride (MCT) oil
Description: A daily dose of 3x12.8g of MCT oil supplementation during a six week intervention period
Study NCT06529367 — intervention group
Intervention type: OTHER
Intervention: Snellen chart
Description: Patients will be asked to use the 5 feet distance for standardization, which allows for visual acuity assessment from 20/16 to 20/200.~Patients will be asked to wear their current corrective lens for distance, to take the test at home in a place with good lighting and to test each eye separately.~Office-based vision testing will be performed by a trained ophthalmic technician in a dimmed room with the Snellen chart illuminated on a screen. Patients will be asked to wear their current corrective lens for distance and an eye occluder will be used to test each eye separately.
Study NCT06073665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine Sodium
Description: Levothyroxine dose will depend on dose at baseline and randomization group
Study NCT06073665 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levothyroxine Sodium
Description: Levothyroxine dose will depend on dose at baseline and randomization group
Study NCT05462756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Efsitora Alfa
Description: Administered SC
Study NCT05462756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro (U100)
Description: Administered SC
Study NCT05462756 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro (U100)
Description: Administered SC
Study NCT05462756 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine (U100)
Description: Administered SC
Study NCT06044298 — intervention group
Intervention type: OTHER
Intervention: procedural sedation
Description: Participants, adverse events during and after gastrointestinal procedures with sedation administered were observed and recorded. No intervention was performed.
Study NCT06535269 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Monopolar Hemorroidecotmy
Description: Hemorrhoidectomy with monopolar diathermy
Study NCT06535269 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Caiman Hemorroidectomy
Description: Hemorrhoidectomy with Caiman® bipolar energy
Study NCT06410573 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breast Self-Examination and Practice
Description: In the training, women will be divided into 5 groups and the training will be held in 5 separate sessions in one day. A training program will be completed with 9 women. All trainings will be conducted under the same conditions in the school's training room. Before the training, women will be informed about the training and their permission and consent will be obtained. The training prepared by the researcher will be presented to the women in the experimental group of the study. The presentation used in the training will include information about breast cancer, breast cancer screening programs and breast self-examination. In the presentation, the steps of breast self-examination will be shown step by step using visual materials.
Study NCT05401292 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hibiclens
Description: antiseptic/antimicrobial skin cleanser for skin wound and general skin cleansing
Study NCT05401292 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isopropyl Alcohol 70% Topical Application Solution
Description: First aid antiseptic
Study NCT06127069 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: chitosan brush
Description: debridement of periodontal pockets with ultrasonic scaler first and after with chitosan brush for 2 minutes
Study NCT05572424 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adaptated Physical Activity (APA) + pedometer watch
Description: Adapted physical activities program : 12 weeks, 2 40-minutes sessions per week ( one broadcast live via online video conferencing and other one in autonomy according to a sequence of different personalized exercises defined by the APA's professional). Children are divided into 6 groups. Each session will be broken down into three parts: the warm-up (10mins), the session's corps alternating between five to eight of muscle strengthening, proprioception, and endurance exercises (20mins) and a cool-down with stretching (10mins). The physical activity performed during the sessions will be quantified with a heart rate monitor and the range of 60-70% of the maximum theoretical heart rate for each child will be respected.~A pedometer watch will wear during 1 year and will provide the number of steps.
Study NCT06340087 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 10% Sucrose
Description: 10% sucrose corresponding to a regular soft drink
Study NCT06340087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sucrose+ Hesperetin
Description: Addition of hesperetin increases sweetness of 7% sucrose solution to match sweetness of 10% sucrose solution
Study NCT06340087 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 7% Sucrose
Description: 7% sucrose to match the caloric content of the sugar-reduced hesperetin intervention
Study NCT06127069 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasonic scaler
Description: debridement of periodontal pockets only with ultrasonic scaler